- Flaws in the U.S. Food and Drug Administration's Rationale for Supporting the Development and Approval of BiDil as a Treatment for Heart Failure Only in Black Patients.George T. H. Ellison, Jay S. Kaufman, Rosemary F. Head, Paul A. Martin & Jonathan D. Kahn - 2008 - Journal of Law, Medicine and Ethics 36 (3):449-457.details
|
|
Race-Based Medicine and Justice as Recognition: Exploring the Phenomenon of BiDil.Joon-ho Yu, Sara Goering & Stephanie M. Fullerton - 2009 - Cambridge Quarterly of Healthcare Ethics 18 (1):57.details
|
|
(1 other version)“Special Treatment”: BiDil, Tuskegee, and the Logic of Race.Susan M. Reverby - 2008 - Journal of Law, Medicine and Ethics 36 (3):478-484.details
|
|
(1 other version)Popular Representations of Race: The News Coverage of BiDil.Timothy Caulfield & Simrat Harry - 2008 - Journal of Law, Medicine and Ethics 36 (3):485-490.details
|
|
(1 other version)“Special Treatment”: BiDil, Tuskegee, and the Logic of Race.Susan M. Reverby - 2008 - Journal of Law, Medicine and Ethics 36 (3):478-484.details
|
|
(1 other version)Popular Representations of Race: The News Coverage of BiDil.Timothy Caulfield & Simrat Harry - 2008 - Journal of Law, Medicine and Ethics 36 (3):485-490.details
|
|
(1 other version)Understanding Race at the Frontier of Pharmaceutical Regulation: An Analysis of the Racial Difference Debate at the ICH.Wen-Hua Kuo - 2008 - Journal of Law, Medicine and Ethics 36 (3):498-505.details
|
|
(1 other version)Understanding Race at the Frontier of Pharmaceutical Regulation: An Analysis of the Racial Difference Debate at the ICH.Wen-Hua Kuo - 2008 - Journal of Law, Medicine and Ethics 36 (3):498-505.details
|
|
Race, Pharmacogenomics, and Marketing: Putting BiDil in Context.Jonathan Kahn - 2006 - American Journal of Bioethics 6 (5):W1-W5.details
|
|
Facts and Fictions: BiDil and the Resurgence of Racial Medicine.Gregory Michael Dorr & David S. Jones - 2008 - Journal of Law, Medicine and Ethics 36 (3):443-448.details
|
|
Patenting Race in a Genomic Age1.Jonathan Kahn - 2008 - Genomics, Society and Policy 4 (3):1-17.details
|
|